Abstract:High-grade serous ovarian cancer (HGSOC) is the most lethal tumor of the female genital tract. Despite extensive studies and the identification of some precursor lesions like serous tubal intraepithelial cancer (STIC) or the deviated mutational status of the patients (BRCA germinal mutation), the pathophysiology of HGSOC and the existence of particular risk factors is still a puzzle. Moreover, a lack of screening programs results in delayed diagnosis, which is accompanied by a secondary chemo-resistance of the tumor and usually results in a high recurrence rate after the primary therapy. Therefore, there is an urgent need to identify the substantial risk factors for both predisposed and low-risk populations of women, as well as to create an economically and clinically justified screening program. This paper reviews the classic and novel risk factors for HGSOC and methods of diagnosis and prediction, including serum biomarkers, the liquid biopsy of circulating tumor cells or circulating tumor DNA, epigenetic markers, exosomes, and genomic and proteomic biomarkers. The novel future complex approach to ovarian cancer diagnosis should be devised based on these findings, and the general outcome of such an approach is proposed and discussed in the paper.

What problem does this paper attempt to address?

The paper primarily explores the risk factors and screening methods related to High-grade Serous Ovarian Cancer (HGSOC). HGSOC is one of the most lethal tumors in the female reproductive system, with its high mortality rate mainly associated with the lack of effective screening programs, delayed diagnosis, high proliferative potential, chemotherapy resistance, and high recurrence rate. ### Problems the Paper Attempts to Address 1. **Identifying Risk Factors for HGSOC**: The paper aims to identify significant risk factors for HGSOC, including genetic and environmental factors, in order to better manage and prevent this cancer. 2. **Developing Screening Programs**: Given the importance of early diagnosis in improving treatment success rates, the paper also attempts to explore methods for developing economically feasible and clinically effective screening programs. 3. **Monitoring Disease Progression**: Additionally, the paper discusses how to use biomarkers to monitor disease progression, so as to detect cancer recurrence as early as possible. ### Overview of Main Content - **Risk Factors**: The paper discusses in detail the epidemiological risk factors for HGSOC (such as age, number of reproductive cycles, etc.), genetic mutations (such as BRCA1/2 mutations), and genetic polymorphisms. It also explores the potential role of the microbiome (including viral, bacterial, fungal, and parasitic infections) in the pathogenesis of HGSOC. - **Diagnostic and Predictive Methods**: The paper reviews various methods used for the diagnosis and prediction of HGSOC, including serum biomarkers, liquid biopsy (circulating tumor cells or circulating tumor DNA), epigenetic markers, exosomes, and genomic and proteomic biomarkers. - **Future Directions**: Finally, the paper proposes a new complex ovarian cancer diagnostic method based on the aforementioned research findings and discusses it. Through these studies, the authors hope to provide new perspectives and strategies for the early diagnosis, risk assessment, and management of patients with HGSOC.

High-Grade Serous Ovarian Cancer—A Risk Factor Puzzle and Screening Fugitive